about
Deconvoluting post-transplant immunity: cell subset-specific mapping reveals pathways for activation and expansion of memory T, monocytes and B cellsBiomarkers for early and late stage chronic allograft nephropathy by proteogenomic profiling of peripheral blood.Cyclosporine-associated thrombotic microangiopathy/hemolytic uremic syndrome following kidney and kidney-pancreas transplantation.Molecular mechanisms of chronic kidney transplant rejection via large-scale proteogenomic analysis of tissue biopsies.Gene Expression in Biopsies of Acute Rejection and Interstitial Fibrosis/Tubular Atrophy Reveals Highly Shared Mechanisms That Correlate With Worse Long-Term Outcomes.Urologic aspects of kidney-pancreas transplantation.Intermediate outcomes of dual renal allografts: the University of Washington experience.Molecular classifiers for acute kidney transplant rejection in peripheral blood by whole genome gene expression profiling.Expression of vascular cell adhesion molecule (VCAM-1) in liver and pancreas allograft rejection.Safety and tolerability of Neoral vs Sandimmune: 1-year data in primary renal allograft recipients. Neoral Study Group.Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.Attitudes and barriers to the use of DCD livers: Comparison of a U.S. transplant center survey to the United Network for Organ Sharing data.The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis.The Current State of Liver Transplantation in the United States: Perspective From American Society of Transplant Surgeons (ASTS) Scientific Studies Committee and Endorsed by ASTS Council.The diagnosis and management of urologic complications in nonrenal transplant recipients.Application of liver transplant and organ procurement techniques to difficult upper abdominal urological cases.Effects of Fragment and Vegetation Structure on the Population Abundance of Ateles hybridus, Alouatta seniculus and Cebus albifrons in Magdalena Valley, Colombia.Rationale for total nephrectomy for suspected renal cell carcinoma.Hepatic intra-arterial infusion of yttrium-90 microspheres in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a case report.Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.Realising resource efficiency in the management of healthcare waste from the Cornwall National Health Service (NHS) in the UK.Hospital readmissions following HLA-incompatible live donor kidney transplantation: A multi-center study.Endoscopic treatment of bladder outlet obstruction in men after pancreas transplantation.Intermediate outcomes of dual renal allografts.Prospective, randomized, multi-center trial of antibody induction therapy in simultaneous pancreas-kidney transplantation.Quantifying the risk of incompatible kidney transplantation: a multicenter study.Morbidity during the first year after pancreas transplantation.Kidney Exchange to Overcome Financial Barriers to Kidney Transplantation.Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.Gating of single molecule transistors: combining field-effect and chemical control.People should not be banned from transplantation only because of their country of origin.Global kidney exchange: Financially incompatible pairs are not transplantable compatible pairs.Ureteral complications in renal transplantation: a comparison of the Lich-Gregoir versus the Taguchi technique.Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group.First-pass metabolism of midazolam by the human intestine.Diversion of the gastroduodenal vein: an in situ model of systemic insulin drainage.Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.Reduction of organ-retrieval damage and organ-discard rates.Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors.
P50
Q28748866-3C0331F8-6EBE-48A3-B91A-4353C07D4EA1Q33480997-8D9049E1-0C85-4A86-8375-1313B153482BQ33497113-CB9991B7-654D-4951-BE44-BCB122BD0401Q33711255-E14CF1D0-64E8-4D92-BAEB-BE46B340D7C2Q33885388-8A089387-74A9-454F-8BF9-18148872B9DAQ34494593-3AF10B98-1261-43CF-A87D-53BAC93F2245Q35063372-DDD3E5E5-2F7E-41B0-BA1A-30B840E4873FQ35629098-F8AA5E9E-01CA-43AC-BEFA-EB6A66D3430AQ35832312-21C7096C-3A3F-4948-9CCF-A3C774058128Q36815206-200BC5C5-1479-499D-824E-EE9DA2FF8FFAQ36827985-00F6EFBD-CEDA-4AC7-A324-49AEB0F206FAQ38611740-F2FFB809-2527-41B1-A31A-ED0136B2185DQ38726037-D008A355-BC0F-489D-8352-E86ADF69B195Q38804947-4CFCA4E6-378E-438D-814C-D0E73489B538Q40653536-001A68F0-8E48-41CC-8257-5A32CF09AD7FQ40755612-4FD1A9D0-093C-452C-ACF4-9831085739F8Q40792218-6233C0EF-8A6F-46D4-B665-07E123E508C9Q40966251-EEC88109-033E-4954-84A3-728C62F5A6E9Q42015157-A7005A85-DF19-4E64-853A-0051A862C1E3Q42153454-ACE121A6-7AE8-4733-A180-84D3B31168E5Q43348876-DE2ED65C-0CD3-40B3-B13B-A27155966BCEQ43475012-D9CD055B-C27E-4949-B5BE-9387ED116F12Q44318461-A61A1C8A-5D8A-403D-AD41-C695283F12AAQ44366799-3B0F71C2-4704-42DC-BC3D-320BF0DB314BQ44482863-0A3590AD-BBA5-4A9C-9FB4-F938D913189FQ44753304-1CE2C8CC-E92E-4BF9-8175-7C1F96A60708Q44918077-362E5362-E9C4-4213-8F42-C4F583E1B1DBQ45049198-3DA3527C-E46E-462E-B255-D66018090B55Q45785880-F0AF5A39-0F4A-4825-A409-AFC043017041Q46629692-6054ECB6-BA07-4BA4-8E23-07EFB686EEA4Q48140037-FBEB5D2D-D0E4-466D-A5C3-C8B283E6C046Q48322808-CE5E01E2-0CD8-4F80-8A13-67A2E35C0126Q50975185-C0C32504-9B6E-48AC-A1A2-EB7DC876015DQ51565001-2E92B091-5BE2-4EE8-A412-F37D765C87A7Q51568384-C8E720C8-9937-40FE-AD3E-C1730D387587Q51620101-693E9D3E-DE65-4069-9B83-B5B0DCAA2D89Q51623373-EA4364C2-EDD8-4E2C-8F46-E067E00E76FFQ51623376-61F089FF-C0A6-4A45-AAC4-0382BA7A0361Q53824121-F84BAD29-2F64-4B06-8A12-EC421FA340C9Q53913637-1682BCC5-19F9-419A-B8CA-70B7568D30CC
P50
description
researcher, ORCID id # 0000-0002-6517-076X
@en
wetenschapper
@nl
name
Christopher L Marsh
@ast
Christopher L Marsh
@en
Christopher L Marsh
@nl
type
label
Christopher L Marsh
@ast
Christopher L Marsh
@en
Christopher L Marsh
@nl
altLabel
Christopher Lee Marsh
@en
prefLabel
Christopher L Marsh
@ast
Christopher L Marsh
@en
Christopher L Marsh
@nl
P106
P21
P31
P496
0000-0002-6517-076X